AI assistant
BeOne Medicines Ltd. — Director's Dealing 2018
Sep 5, 2018
30073_dirs_2018-09-05_7acd66d4-5690-431e-a907-167b1a856477.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2018-09-04
Reporting Person: Huang Jane (CMO, Hematology)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-09-04 | American Depositary Shares | S | 2911 | $174.5953 | Disposed | 0 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Ordinary Shares | 271621 | Direct |
Footnotes
F1: Each American Depositary Share represents 13 Ordinary Shares.
F2: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.52 to $174.881, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.